Penny stocks are often written off as lottery tickets, but rising global rate pressures, uneven inflation trends and mixed growth data are putting a premium on strong balance sheets and access to cash. That is where the Elite Penny Stocks screener stands out. It filters for lower priced stocks that actually look funded to pursue their growth plans, rather than relying on hope and dilution. For investors who want exposure to higher risk and higher potential ideas without guessing blindly, this curated list can be a useful starting point. Below, you will see 3 of the best stocks from the screener and why they stand out.

Grab Holdings (GRAB)

Overview: Grab Holdings runs a superapp used across Southeast Asia that brings together ride-hailing, food and grocery delivery, digital payments, banking, lending, insurance and advertising in a single consumer and merchant platform.

Operations: Grab generates most of its revenue from Deliveries at US$1.9b and Mobility at US$1.3b, with smaller contributions from Financial Services at US$379m and Others at US$4m.

Market Cap: US$14.2b

Grab Holdings deserves attention because it is deeply embedded in everyday spending in Southeast Asia, from transport and food to payments and lending, yet still carries some funding and governance risks that investors should weigh carefully. Earnings growth has been very strong in recent periods, profit margins have improved from 0.8% to 10.7% and the balance between high growth expectations, a premium P/E multiple and mixed recent share price performance creates an interesting tension for anyone using the Elite Penny Stocks screener. At the same time, reliance on higher risk external borrowing, relatively low current and forecast ROE and a board that is still early in its tenure mean the full risk reward profile of Grab stock is not as simple as the headline numbers suggest.

Grab Holdings’ fast improving margins and everyday presence across Southeast Asia raise big questions about what the market is really pricing in, so tap into the full risk reward picture with the 4 key rewards and 1 important major warning sign

Niagen Bioscience (NAGE)

Overview: Niagen Bioscience develops and sells science backed healthy aging products built around its proprietary NAD+ boosting ingredient, nicotinamide riboside, supplying both branded supplements like TRU NIAGEN to consumers and raw ingredient technologies to other manufacturers, clinics and healthcare practitioners.

Operations: Niagen Bioscience generates most of its revenue from Consumer Products at US$98.6m, with additional contributions from Ingredients at US$29.1m, Analytical Reference Standards and Services at US$2.7m, and a small Segment Adjustment of US$0.1m.

Market Cap: US$280.9m

Niagen Bioscience stands out in the Elite Penny Stocks screener because it ties a focused healthy aging story to tangible financial traction, with net profit margins of 14.3% and a 22.6% ROE supporting the case that its NAD+ platform is more than just hype. Reported forecasts indicate that earnings and revenue are both expected to grow faster than the broader US market, supported by expanding distribution through more than 8,000 practitioners, new Niagen Plus injection and telehealth offerings, and additional clinic partnerships that can lift average revenue per customer. At the same time, heavy reliance on external borrowing and a recent US$6.8m one off gain highlight the importance of distinguishing durable profitability from short term boosts and considering the level of confidence in the assumptions underlying these growth expectations.

Niagen Bioscience’s healthy aging story is accelerating, but the real question is how solid those margins and borrowing choices look side by side. Line up the full picture with the 3 key rewards and 1 important warning sign

Clover Health Investments (CLOV)

Overview: Clover Health Investments runs Medicare Advantage plans in the United States and offers preferred provider organization and health maintenance organization options to Medicare-eligible individuals, supported by its Clover Assistant software that helps physicians spot and manage chronic diseases more effectively.

Operations: Clover Health Investments generates all of its US$2.2b in revenue from Insurance operations in the United States.

Market Cap: US$2.6b

Clover Health Investments is drawing interest because it sits at the intersection of Medicare Advantage activity and technology-driven healthcare, with its Clover Assistant platform designed to reduce medical costs and support new, higher margin revenue streams. Recent upgrades to a 4.5 star rating for key plans and court-ordered recalculations of star scores are expected to influence bonus payments and reimbursements. At the same time, investors need to weigh funding risk from a debt-heavy balance sheet, ongoing GAAP losses and recent insider selling, which together make the gap between current pricing and estimated fair value a higher stakes opportunity rather than a simple bargain.

Clover Health’s 4.5 star plans and tech driven Medicare approach could be masking a very different long term story about margins and funding risk, so line up the moving parts with the analysis report for Clover Health Investments

The three stocks highlighted here are only a sample of what the full Elite Penny Stocks screener uncovered, with the complete Elite Penny Stocks screener revealing 20 more companies that pair funding strength with equally compelling narratives around growth catalysts. Use Simply Wall St to identify, filter and analyze the specific catalysts, balance sheet traits and narrative drivers that matter to you so you can focus on the highest conviction ideas in this higher risk corner of the market.

Take Control of Your Investment Journey

If Clover Health Investments or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh opportunities do not wait, and the next breakout stories can be flying under the radar for now. Scan these focused stock lists before the momentum is caught, and consider acting sooner rather than later.

• Spot cash rich companies holding their ground while others are dropping by running the list of solid balance sheet and fundamentals (48 results) and isolating businesses with stronger financial foundations.
• Explore structural demand for critical metals by checking the 32 best rare earth metal stocks and identifying producers that are part of longer term technology and energy themes.
• Look for real cash returns by scanning the 9 dividend fortresses and focusing on companies offering higher yields with an emphasis on durability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.